why choose us

First received: February 8, 2023

Clinical Trial: Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients

Study Status: Active, not recruiting

Recruit Status: Active, not recruiting

Condition: Chronic Kidney Diseases
Bone Diseases, Metabolic

Study Type: Interventional


Official Title: Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Kidney Disease Progression and Bone Mineral Metabolism in Non-diabetic Patients With Chronic Kidney Disease

Brief Summary: It is a randomized controlled trial in which 100 non diabetic chronic kidney disease (CKD) patient is being participated.Their estimated glomerular filtration rate (eGFR) between 25-75 ml/min/1.73 m2.Participants will be randomized into two groups:Study group: includes 50 patients, they will receive Sodium glucose co-transporter 2 inhibitor (SGLT2i) as add on drug, Dapagliflozin 10 mg will be used once daily with or without food.Control group: includes 50 patients, they will receive placebo their medication.The…

Read more